论文部分内容阅读
目的研究凋亡抑制蛋白Bcl-2在弥漫大B细胞淋巴瘤中的表达和临床意义。方法采用免疫组织化学法对84例DLBCL石蜡标本进行Bcl-2检测,另取20例淋巴结反应性增生(RH)作为对照组。结果 Bcl-2在DLBCL中的表达率58.3%(49/84)明显高于淋巴结反应性增生40%(8/20),两者差异没有统计学意义(P>0.05);Bcl-2在DLBCL中的表达与患者年龄、性别无关(P>0.05),但与首发部位、临床分期、IPI分级、血清LDH水平、结外病灶数目有关(P<0.05)。结论 Bcl-2参与DLBCL的发生发展,可能是判断预后极有价值的指标。
Objective To study the expression of Bcl-2 in diffuse large B cell lymphoma and its clinical significance. Methods Bcl-2 was detected by immunohistochemistry in 84 cases of DLBCL paraffin specimens. Another 20 cases of lymph node reactive hyperplasia (RH) were used as the control group. Results The expression of Bcl-2 in DLBCL was significantly higher than that in lymph node reactive hyperplasia (58.3%, 49/84, 40%, 8/20) (P> 0.05) (P> 0.05). However, it was related to the initial site, clinical stage, IPI grade, serum LDH level and number of extranodal lesions (P <0.05). Conclusion Bcl-2 is involved in the occurrence and development of DLBCL and may be an extremely valuable indicator for prognosis.